In particular, 11/23 (i.e., 47.8%) tumors showed PD-L1 expression on tumor cells (TPS mean: 49.09 ± 24.06%) whereas CPS score, which includes PD-L1 expression both in tumor and immune cells, was positive in almost all cases (i.e., 19/20), with high expression detected in 13/19 patients (CPS mean: 40.3 ± 34.84). This evidence concerns the gene CD274 and neoplasm.